CD4 and eosinophilic esophagitis: BT-11 (piperazine-1,4-diylbis((6-(1H-benzo[d]imidazol2-yl)pyridin-2-yl)methanone) dihydrochloride), an oral, gut-restricted, small molecule that activates lanthionine synthetase C-like 2 (LANCL2) (Leber et al., 2019), has demonstrated to be able to lead to an increase in number and function of regulatory CD4 + T cells (Tregs) in Inflammatory bowel disease (IBD) and is programmed to be tested in EoE patients in a phase Ib study (NCT04835168) planned to start in January 2022.5